| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 5, 2024 |
| Accession Number: | 0001553350-24-000071 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
Agreement expands Cardio Diagnostics' global footprint and supports improved detection and management of coronary heart disease in India. Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), a leader in epigenetics and AI-driven Precision Cardiovascular Medicine, Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932, introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India, and Dr. Lal PathLabs, one of India's most trusted service provider of diagnostic and related healthcare tests with 290+ clinical laboratories and 300+ MD pathologists in their internal network, today announced a stra
Southdale YMCA, part of YMCA of the North, becomes the second YMCA location nationally to partner with Cardio Diagnostics, expanding community access to AI-powered cardiovascular testing and education Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced a new partnership with the Southdale YMCA to bring expanded heart health education and advanced cardiovascular testing to their members and the broader Edina community. The Southdale YMCA primarily serves the Edina, Richfield, Bloomington, and South Minneapolis areas, supporting more than 14,000 individuals, approximately 80% of whom are adults. This collaboration build
The final gapfill payment rate for both the Epi+Gen CHD™ and PrecisionCHD™ tests is higher at $854 compared to the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™. Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a final gapfill payment rate of $854 for both the Epi+Gen CHD™ and PrecisionCHD™ tests. This finalized rate represents an increase from the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™. Obtaining the final rate represents a positive development and will be e
10-Q - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
424B3 - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor. Dr. Ramjee is a cardiologist and a health innovation leader, serving as the National Co-Chair of Cardiology and Innovation at CommonSpirit Health Enterprise and is also a member of the American Heart Association Board of Directors. The appointment of Dr. Ramjee as a Strategic Advisor to Cardio Diagnostics is a significant development to the Company's continued growth and market expansion. He brings a wealth of experience and proven track record in clinical practice, innovation and research, makin
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director. Mr. Burton will Chair the Nominating and Corporate Governance Committee and will also serve as a member of the Audit Committee. Mr. Burton is the Managing Partner at 2Flo Ventures, an early-stage healthcare investor and startup studio focused on accelerating health equity. He is also the CEO of Akan Biosciences, a clinical-stage biotech company, and runs an advisory firm working closely with healthcare growth companies. Mr. Burton brings over 20 years of experience in medical
SC 13G/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)